Modulation of D1-like dopamine receptor function by aldehydic products of lipid peroxidation.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 12644268)

Published in Brain Res on April 04, 2003

Authors

Yangmee Shin1, Beatrix H White, Misook Uh, Anita Sidhu

Author Affiliations

1: Department of Pediatrics, Georgetown University Medical Center, 3970 Reservoir Road, N.W., 20057, Washington, DC, USA.

Articles by these authors

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol (2010) 2.13

Differential expression of D2-like dopamine receptors in the kidney of the spontaneously hypertensive rat. J Hypertens (2003) 1.58

Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett (2003) 1.42

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J (2009) 1.42

Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. ChemMedChem (2006) 1.37

An inflammatory pathomechanism for Parkinson's disease? Curr Med Chem (2006) 1.20

Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci (2011) 1.14

Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry (2005) 1.14

Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J (2003) 1.07

Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J (2006) 1.06

Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein. Eur J Neurosci (2006) 1.04

Synuclein modulation of monoamine transporters. FEBS Lett (2011) 1.01

The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system. Ann N Y Acad Sci (2004) 1.00

Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein. Eur J Neurosci (2006) 0.99

The neurotoxin, MPP+, induces hyperphosphorylation of Tau, in the presence of alpha-Synuclein, in SH-SY5Y neuroblastoma cells. Neurotox Res (2006) 0.99

D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem (2004) 0.98

Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease. PLoS One (2011) 0.98

Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways. PLoS One (2012) 0.97

Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Mol Cell Neurosci (2003) 0.96

Desipramine modulation of alpha-, gamma-synuclein, and the norepinephrine transporter in an animal model of depression. Neuropsychopharmacology (2008) 0.96

Regulation of the norepinephrine transporter by alpha-synuclein-mediated interactions with microtubules. Eur J Neurosci (2007) 0.94

Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J Neurosci Res (2010) 0.93

Dopamine promotes striatal neuronal apoptotic death via ERK signaling cascades. Eur J Neurosci (2009) 0.92

Regulated interactions of the norepineprhine transporter by the actin and microtubule cytoskeletons. J Neurochem (2008) 0.91

Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant. Biochemistry (2004) 0.89

Abnormal migration of human wild-type alpha-synuclein upon gel electrophoresis. Neurosci Lett (2004) 0.89

Inflammation and Parkinson's disease. Curr Drug Targets Inflamm Allergy (2002) 0.87

Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Biochemistry (2004) 0.87

Partial regulation of serotonin transporter function by gamma-synuclein. Neurosci Lett (2009) 0.84

Comparative analyses of alpha-synuclein expression levels in rat brain tissues and transfected cells. Neurosci Lett (2004) 0.84

Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity. J Biol Chem (2003) 0.83

Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation. Mol Cell Neurosci (2004) 0.83

Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function. PLoS One (2013) 0.83

Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. BMC Neurosci (2011) 0.83

Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease. Biochem Biophys Res Commun (2007) 0.82

Dopamine D1 receptor-mediated toxicity in human SK-N-MC neuroblastoma cells. Neurochem Int (2005) 0.81

Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson's disease-linked mutants. Neurosci Lett (2003) 0.81

Overexpression of inducible nitric oxide synthase in the kidney of the spontaneously hypertensive rat. Clin Exp Hypertens (2005) 0.80

Desipramine induced changes in the norepinephrine transporter, alpha- and gamma-synuclein in the hippocampus, amygdala and striatum. Neurosci Lett (2009) 0.80

Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PLoS One (2013) 0.79

Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS One (2013) 0.78

Diminished expression of constitutive nitric oxide synthases in the kidney of spontaneously hypertensive rat. Clin Exp Hypertens (2003) 0.78

Delineation of the conserved functional properties of D1A, D1B and D1C dopamine receptor subtypes in vertebrates. Biol Cell (2004) 0.78

Alterations of striatal glutamate transmission in rotenone-treated mice: MRI/MRS in vivo studies. Exp Neurol (2007) 0.76